Microfluidic Blood Labyrinth Barrier Model for Inner Ear Drug Testing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods face challenges in delivering therapeutics to the inner ear's cochlea and vestibular system due to their inaccessibility and the risk of ototoxicity from systemic delivery, with no effective drug therapies available to protect or restore hearing in cases of sensorineural hearing loss.
Innovation Solution
A microfluidic device modeling the human ear's blood labyrinth barrier, comprising endothelial cells, pericytes, and perivascular macrophage-like melanocytes, which simulates the barrier's structure and function, allowing for medical assessments and experiments to evaluate therapeutic delivery and ototoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If systemic delivery of therapeutics is used to treat inner ear diseases, then the treatment can be administered through common routes (oral, intravenous), but the therapeutics cannot reach the cochlea and vestibular system effectively due to the blood labyrinth barrier, and off-target binding causing ototoxicity occurs
Solution Approach 1:
The patent creates an in vitro model of the blood labyrinth barrier using a microfluidic device with a porous membrane that replicates the barrier's structure and function. This model allows researchers to study therapeutic delivery and ototoxicity mechanisms without needing to access the actual inner ear, enabling experimentation with various delivery routes and compounds in a controlled environment that mirrors human physiology
Solution Approach 2:
The porous membrane in the microfluidic device serves as an intermediary that simulates the blood labyrinth barrier. It allows selective transport of substances from the systemic circulation side to the cochlear side, replicating the barrier's selective permeability and enabling the study of how different therapeutics navigate or are blocked by the barrier
2Reliability
If animal models are used to study inner ear diseases and therapeutic delivery, then relevant biological data can be obtained, but animal testing is ethically problematic and does not fully translate to human results
Solution Approach 1:
The microfluidic device creates a simplified copy of the blood labyrinth barrier system using human cells (endothelial cells, pericytes, and perivascular macrophages) arranged in a microfluidic channel with a porous membrane. This human-based model eliminates the need for animal testing while maintaining biological relevance through the use of authentic human cell types and their physiological interactions
Solution Approach 2:
The device segments the complex inner ear system into its critical functional components: a porous membrane representing the barrier, endothelial cells forming the vascular lining, pericytes providing structural support, and perivascular macrophages for immune surveillance. This segmentation allows each component to be studied independently while maintaining overall system functionality
3Reliability
If the blood labyrinth barrier is disrupted to improve therapeutic delivery to the cochlea, then more drugs can reach the target, but inner ear homeostasis is compromised and ototoxicity increases
Solution Approach 1:
The microfluidic device enables real-time monitoring of barrier integrity and therapeutic delivery dynamics. Researchers can adjust delivery parameters, compound concentrations, and flow rates to optimize therapeutic penetration while maintaining barrier function, using feedback from the model to prevent ototoxicity and preserve homeostasis
Solution Approach 2:
The device allows systematic variation of physical and chemical parameters such as pressure gradients, flow rates, temperature, and compound concentrations to identify optimal delivery conditions. By controlling these parameters, researchers can enhance therapeutic penetration while maintaining barrier integrity and avoiding ototoxic effects
Data Source
AI summary
A device is disclosed for modelling a blood labyrinth barrier of a human ear that includes a first fluid channel and a second fluid channel, and a membrane separating the first and second fluid channels. The membrane has a luminal side in the first fluid channel and an abluminal side in the second fluid channel, endothelial cells attached to the luminal side of the membrane, pericytes attached to the abluminal side of the membrane, and perivascular macrophage-type melanocytes arranged in the second fluid channel. A method of preparing such device is also disclosed. As well, a device with two fluid channels and a membrane as described above is disclosed, wherein the endothelial cells, pericytes and perivascular macrophage-type melanocytes are arranged in two fluid containers.